OncoCheck: Advancing Precision Oncology Through Genomic Insights

by Posted on

Cancer remains one of the world’s leading health challenges, accounting for millions of new diagnoses every year. While traditional diagnostic approaches rely heavily on histopathology and imaging, modern oncology increasingly depends on understanding the molecular drivers behind tumour development. Genomic Insights using high-throughput NGS has emerged as a cornerstone of precision medicine, enabling clinicians to tailor treatment strategies based on the specific genetic alterations present in a patient’s cancer.

Recognizing this need, Genes2Me has developed OncoCheck™, a comprehensive 53-gene NGS assay that delivers high-confidence genomic insights to support precision oncology. Designed for clinical and research laboratories, the assay combines advanced sequencing technology with streamlined analysis to enable accurate detection of clinically relevant variants.

The Need for Precision Genomic Analysis

Cancer is not a single disease but a collection of genetically diverse disorders. Even patients diagnosed with the same type and stage of cancer can harbor distinct genomic alterations that influence disease progression, prognosis, and response to therapy. As a result, understanding the molecular profile of a tumor has become fundamental to precision oncology. Precision Genomic Analysis powered by next-generation sequencing (NGS), enables simultaneous analysis of multiple cancer-associated genes, providing a holistic view of the genomic alterations driving an individual’s cancer.

Identifying these genomic alterations is essential for:

  • Selecting targeted therapies
  • Supporting personalized treatment planning
  • Identifying prognostic biomarkers
  • Guiding enrolment in precision medicine clinical trials
  • Monitoring disease progression and therapeutic response

By detecting multiple classes of genomic variants in a single assay, it helps clinicians make more informed decisions while reducing the need for sequential single-gene testing and conserving valuable patient samples.

As the landscape of precision oncology continues to evolve and the number of clinically actionable biomarkers expands, Precision Genomic Analysis has become an indispensable component of routine cancer care. It bridges the gap between genomic science and clinical practice, empowering healthcare professionals with actionable molecular insights that drive accurate diagnosis, individualized treatment strategies, and ultimately, improved patient outcomes.

Introducing OncoCheck™

OncoCheck™ is a targeted oncology sequencing solution designed to provide broad and clinically meaningful genomic coverage through a carefully curated panel of 53 cancer-associated genes.

Using hybrid-capture enrichment technology, the assay offers excellent target uniformity and reliable detection of key germline and somatic alterations. The panel is optimized to identify:

  • Single Nucleotide Variants (SNVs)
  • Insertions and Deletions (InDels)
  • Copy Number Variations (CNVs)

By consolidating multiple variant classes into a single workflow, OncoCheck™ helps laboratories maximize efficiency while generating critical molecular insights.

Key Features That Set OncoCheck™ Apart

Comprehensive 53-Gene Panel

The assay targets clinically significant genes frequently implicated across multiple solid tumors, enabling broad genomic characterization from a single test.

Advanced Hybrid-Capture Technology

Hybrid-capture chemistry provides improved specificity and uniform coverage compared to amplification-based methods, ensuring consistent sequencing performance across targeted regions.

Detection of Multiple Variant Types

Rather than focusing on a single mutation class, OncoCheck™ simultaneously identifies SNVs, InDels, and CNVs, offering a more complete molecular profile for clinical interpretation.

Broad Sample Compatibility

The workflow supports a variety of clinically relevant sample types, including:

  • Formalin-Fixed Paraffin-Embedded (FFPE) tissue
  • Fresh tissue samples
  • Blood-derived DNA

This flexibility allows laboratories to integrate the assay into diverse oncology testing workflows.

High-Confidence Bioinformatics Analysis

Cliseq® Interpreter is Genes2Me’s advanced bioinformatics analysis and interpretation platform that complements the OncoCheck™ assay by converting complex sequencing data into clinically actionable insights. By simplifying data analysis and generating comprehensive, easy-to-interpret reports, Cliseq® Interpreter enhances laboratory efficiency and supports informed decision-making in precision oncology

Supporting Precision Medicine

Precision oncology focuses on matching the right patient with the right therapy at the right time. Genomic testing plays a central role in achieving this objective by identifying actionable mutations that may influence therapeutic decisions.

By delivering comprehensive molecular information, OncoCheck™ supports clinicians in:

  • Understanding tumor biology
  • Identifying clinically actionable variants
  • Evaluating potential targeted treatment options
  • Improving confidence in personalized patient management

As molecular diagnostics continue to reshape oncology practice, Precision Genomic Analysis is becoming an essential component of evidence-based care.

Simplifying Laboratory Workflows

Modern molecular laboratories require solutions that balance analytical performance with operational efficiency. OncoCheck™ has been designed with this objective in mind.

Its optimized workflow, broad platform compatibility, and integrated analysis support enable laboratories to reduce complexity while maintaining high analytical standards. This streamlined approach can improve turnaround time and operational productivity without compromising data quality.

The Future of Oncology Diagnostics

Cancer diagnostics are rapidly evolving from morphology-based evaluation to genome-driven clinical decision-making. As targeted therapies and biomarker-guided treatment strategies continue to expand, the demand for reliable genomic testing will only increase.

The NGS assays such as OncoCheck™ are helping bridge the gap between complex genomic data and practical clinical application. By providing accurate detection of clinically relevant variants within a focused 53-gene panel, the assay equips healthcare professionals with the information needed to support informed treatment decisions and personalized cancer care.

Conclusion

The future of oncology lies in precision medicine, where treatment decisions are informed by the unique molecular characteristics of every patient’s disease. OncoCheck™ from Genes2Me embodies this vision by delivering comprehensive, high-confidence genomic profiling through a clinically relevant 53-gene NGS panel.

With advanced hybrid-capture technology, multi-variant detection capabilities, broad sample compatibility, and robust bioinformatics support, OncoCheck™ provides laboratories and clinicians with a powerful tool for precision oncology.

Because every genomic insight has the potential to shape a better clinical decision—and every better decision can make a meaningful difference in a patient’s journey.

Published by Genes2Me

Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry’s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics—delivering integrated solutions that advance precision medicine and improve lives worldwide.